 |
|
|
| |
NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non-
Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Sudha Shankar1, Mustafa R. Bashir2, Bryan A. Baxter1, Van Phung1, Andrew Z. Yan1, Stephen J. Rossi1, and Alex M. DePaoli1
1NGM Biopharmaceuticals, South San Francisco, CA 2Duke University, Durham, NC
|
| |
|
|
|
|
|
